Clawback is the single biggest commercial variable in the Greek pharmaceutical market. The rules for the rest of this decade were quietly rewritten in late 2025 — and the new formula is less generous than the one it replaced.
The mechanism is simple to state and painful to absorb: where public pharmaceutical spending exceeds the statutory ceiling, the industry automatically repays the excess. It rests on Article 11 of Law 4052/2012, with ceilings and adjustment rules in Article 25 of Law 4549/2018 and rebates under Article 35 of Law 3918/2011. Definitive calculation is made on a six-monthly basis.
What actually changed
A common misconception is that the 2022-2025 framework expired at the end of 2025 and left a gap. It did not. Law 5243/2025 amended Article 25(2) of Law 4549/2018 so that for the years 2023 to 2030, the permitted spending limits are adjusted solely by the projected annual change in real GDP as reflected in each year’s budget — and, specifically for each of the years 2026 to 2030, the resulting limit is increased by a flat €100 million.
Compare that with what came before. The 2022-2025 arrangement provided escalating top-ups — rising year on year to €400 million by 2025. The successor replaces that escalator with a flat €100 million per year on top of GDP indexation. For companies modelling exposure to 2030, this is a materially different — and tighter — structure.
How the ceiling is divided
The annual allocation across categories — EOPYY hospital pharmaceutical spending on high-cost medicines, other EOPYY pharmaceutical spending, EOPYY health services and the hospital pharmaceutical spending of ESY hospitals — is set each year by joint ministerial decision. The formula is in law; the actual numbers are not, and they must be tracked annually.
The R&D offset — and its catch
A joint ministerial decision of March 2026 set the terms for offsetting clawback against research, development and investment expenditure for 2026-2027, with a budget of €150 million, administered through the General Secretariat for Research and Innovation. Projects must be completed by 31 December 2028, achieving at least 70% of both physical and financial targets.
The catch is eligibility. As drafted, the offset is available to Greek parent companies subject to clawback — which excludes foreign multinational parents operating through Greek subsidiaries. Industry has objected publicly, both to that exclusion and to the feasibility of the deadline and the 70% threshold. If you are structured as a local subsidiary, check carefully before assuming you can benefit.
Other 2026 developments
From 1 January 2026 the Ministry of National Defence and NIMTS were brought inside the clawback and rebate mechanisms, with their own hospital pharmaceutical ceilings. Law 5302/2026 also allows the state budget to advance funds against the ceiling increase within the first half of each year, capped at half the amount allocated.
How PQRA helps
PQRA models clawback exposure, advises on pricing and access strategy in a capped market, and helps companies navigate the offset and negotiation routes available.
No responses yet